Clinical Trials for Solid Tumors
TRIDENT-1
A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements (TRIDENT-1). View Details.
Medical Oncology: 706.353.2990
Radiation Oncology: 706.548.0500
Surgical Oncology: 706.715.2430
Breast Health Program: 762.356.4780
Pharmacy: 706.353.4344
Referrals: 706.353.4346
A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements (TRIDENT-1). View Details.